Beam Therapeutics Target Price

See Beam Therapeutics's analyst price targets ($60) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$23.99

Average Target Price

$59.50

148% upside

2 analysts in the last 4 months

High: $80 | Low: $39

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-05-21	H.C. WainwrightPatrick Trucchio	$80	233.5% upside
2026-05-13	Tudor PickeringWilliam Pickering	$39	62.6% upside
2026-02-25	RBC Capital	$26	8.4% upside
2026-02-20	Canaccord Genuity	$74	208.5% upside
2026-01-21	Tudor PickeringWilliam Pickering	$41	70.9% upside
2026-01-20	Bernstein	$41	70.9% upside
2026-01-07	UBSMichael Yee	$28	16.7% upside
2025-11-24	Evercore ISI	$35	45.9% upside
2025-10-09	Jefferies	$41	70.9% upside
2025-05-07	GuggenheimDebjit Chattopadhyay	$55	129.3% upside
2025-03-03	Scotiabank	$25	4.2% upside
2025-01-07	Tudor PickeringWilliam Pickering	$37	54.2% upside
2024-11-06	Leerink PartnersRick Bienkowski	$39	62.6% upside
2024-11-05	BMO CapitalKostas Biliouris	$57	137.6% upside
2024-09-11	Stifel NicolausBenjamin Burnett	$69	187.6% upside
2023-02-01	Cantor Fitzgerald	$62	158.4% upside
2022-12-20	BMO CapitalKostas Biliouris	$66	175.1% upside
2022-12-13	Citigroup	$62	158.4% upside
2022-04-28	Credit Suisse	$62	158.4% upside

Beam Therapeutics (BEAM) FAQ

Beam Therapeutics posts a target price of $60. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $60 for BEAM means covering analysts, on average, see the stock 148.0% upside of $23.99 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BEAM's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Beam Therapeutics's other metric pages and overview cover the third.

Judging Beam Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $60 here, then scan peer and history charts to see if the gap is persistent.